Viral Clearance Studies: Challenges and Beyond: The design of viral clearance studies must keep pace with the quickly evolving biologic drugs industry.
| Publicado en: | BioPharm International Vol. 35; no. 12; pp. 18 - 22 |
|---|---|
| Autores principales: | , |
| Formato: | pictorial tables/charts Journal Article |
| Publicado: |
MJH Life Sciences
Dec2022
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=160656719&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 160656719 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 1542166X 5NE jtl: BioPharm International issn: 1542166X maglogo: N pubinfo: dt: Dec2022 vid: 35 iid: 12 pid: 54670 pub: MJH Life Sciences place: Cranbury, New Jersey artinfo: ui: 160656719 160656719 160656719 160656719 ppf: 18 ppct: 4 formats: fmt: @attributes: type: P tig: atl: Viral Clearance Studies: Challenges and Beyond: The design of viral clearance studies must keep pace with the quickly evolving biologic drugs industry. aug: au: JABER, TAREQ TESSARZ, ANJA affil: Associate director, Charles River Laboratories sug: subj: Pharmaceutical Companies Antiviral Agents Viral Load pubtype: Trade Publication doctype: pictorial tables/charts Journal Article ougenre: Article ab: language: English refInfo: holdings: @attributes: islocal: N |
|---|